Clinical trial
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial…
NCT00390728 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00390728 |
|---|---|
| Title | Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial) |
| Official title | A Phase IIIb/IV, Multinational, Multicentre, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With… |
| Acronym | AT-LANTUS |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1 |
| Intervention type | Drug |
| Interventions | Insulin Glargine |
| Enrollment | 2,346 |
| Start date | Apr 1, 2002 |
| Primary completion | Aug 1, 2003 |
| Completion | Aug 1, 2003 |
| First posted | Oct 20, 2006 |
| Last update posted | Aug 31, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: